News & views
Our collective understanding of mental health is increasing all the time, with advances in neuroscience, psychotherapy, psychopharmacology and digital platforms.
For media inquiries, contact us at media@compasspathways.com

May 26, 2023
Data demonstrating long-term improvement in depression in cancer patients following single dose of COMP360 psilocybin therapy to be presented at ASCO 2023

May 11, 2023
COMPASS Pathways Announces First Quarter 2023 Financial Results and Business Highlights

February 28, 2023
COMPASS Pathways Announces Fourth Quarter and Year-End 2022 Financial Results and Business Highlights

December 08, 2022
COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented at ACNP

November 03, 2022
COMPASS Pathways Announces Third Quarter 2022 Financial Results and Business Highlights

November 03, 2022
COMPASS Pathways announces publication of phase 2b study of COMP360 psilocybin therapy for treatment-resistant depression in The New England Journal of Medicine

October 27, 2022
COMPASS Pathways plc to announce third quarter 2022 financial results on 3 November 2022

October 12, 2022
COMPASS Pathways Announces Phase 3 Pivotal Program Design for COMP360 in Treatment Resistant Depression at Capital Markets Day
Looking for older news & views posts? View COMPASS news archive